Sickle Cell Treatment Demonstration Program
Program Funding
Annual program obligations reported to SAM.gov.
Who has received this funding
Organizations awarded under CFDA 93.365 (USAspending.gov).
- The Johns Hopkins University $8,565,453
- Childrens Hospital Medical Center $6,266,000
- Washington University, The $6,265,971
- University Of Alabama At Birmingham $6,219,000
- The Center For Comprehensive Care & Diagnosis Of Inherited Blood Disorders $5,908,498
- The Charlotte-Mecklenburg Hospital Authority $2,037,715
Funded Projects
Examples of what this program has supported.
From 2023 - 2024, eighty percent of individuals with SCD seen by a provider within the sickle cell treatment demonstration program received the disease modifying therapies as a result of improved access and connection to ongoing care and management.
Program Objective
The objectives of this project is to support the development and establishment of systemic mechanisms to improve the prevention and treatment of sickle cell disease complications, including the coordination of service delivery for individuals with sickle cell disease; genetic counseling and testing; bundling of technical services related to the prevention and treatment of sickle cell disease; training of health professionals; and identifying and establishing efforts related to the expansion and coordination of education, treatment, and continuity of care for individuals with Sickle Cell Disease as authorized in 42 USC Section 300b-5(b) (Section 1106(b) of the Public Health Service Act).
Eligibility
Eligible Applicants
- Nonprofit Organization
- Other
Eligible entities include, Federally-qualified health center, as defined in section 1905(10(2)(B) of the Social Security Act (42 U.S.C. 1396d(10(2)(B), nonprofit hospital or clinic, or university health center that provides primary health care, that: (1) has a collaborative agreement with a community-based Sickle Cell Disease organization or a nonprofit entity with experience in working with individuals who have Sickle Cell Disease; and (2) demonstrates that either the Federally-qualified health center, the nonprofit hospital or clinic, the university health center, the community-based Sickle Cell Disease organization or the Sickle Cell Disease experts who serve as consultants to the project have at least 5 years of experience in working with individuals who have Sickle Cell Disease.
Beneficiaries
- Health Professional
- Unrestricted by Individual Type
- Other
Specialized group (e.g. health professionals, students, veterans), Health Professional, Physically Afflicted (e.g. TB, Arthritis, Heart Disease), Public nonprofit institution/organization
Projects will benefit individuals with Sickle Cell Disease and health professionals who provide care for individuals with Sickle Cell Disease.
How to Apply
Award Procedure
All qualified applications will be forwarded to an objective review committee. Based on the recommendations of the objective review committee, the HRSA program official with delegated authority is responsible for final selection and funding decisions. Notification is made in writing by a Notice of Award.
Decision Timeline
- Approval: From 120 to 180 days
Final decisions are made 4 to 6 months after receipt of applications.
Program details & compliance
Description
The objectives of this project is to support the development and establishment of systemic mechanisms to improve the prevention and treatment of sickle cell disease complications, including the coordination of service delivery for individuals with sickle cell disease; genetic counseling and testing; bundling of technical services related to the prevention and treatment of sickle cell disease; training of health professionals; and identifying and establishing efforts related to the expansion and coordination of education, treatment, and continuity of care for individuals with Sickle Cell Disease as authorized in 42 USC Section 300b-5(b) (Section 1106(b) of the Public Health Service Act).
Mission Categories
Primary: General Health and Medical
Use of Funds
Allowed Uses
All funds granted should be expended solely for carrying out the approved projects in accordance with Section 712 of the Public Law 103-357.
Required Documentation
Applicants should review the individual HRSA notice of funding opportunity issued under this Assistance Listing program for any required proof or certifications which must be submitted prior to or simultaneous with submission of an application package. 2 CFR 200, Subpart E - Cost Principles applies to this program.
Reporting & Compliance
Applicable 2 CFR 200 Subparts
- Subpart B — General Provisions
- Subpart C — Pre-Federal Award Requirements
- Subpart D — Post-Federal Award Requirements
- Subpart E — Cost Principles
- Subpart F — Audit Requirements